Keros Therapeutics, Inc. (KROS:NASDAQ) closed at $10.30 on November 13, 2026, up 2.18% on the day. The stock trades 54.3% below its 52-week high of $22.55 and 14.7% above its 52-week low of $8.98. Over the past year, it lost 40.3%. Keros Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, KROS closed higher on 117 days (46%). Its best day was December 4, 2025 (+11.99%) and its worst was March 5, 2026 (-14.96%). The stock moved 10% or more in a single session 5 times.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Find more stocks like KROS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.